Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 known ✓ | P08588 | 5/20 | 0.97 |
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.65 |
| ▸ | HTR1D known ✓ | P28221 | 1/20 | 0.65 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.65 |
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 0.64 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.64 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.57 |
| ▸ | HTR2C | P28335 | 3/20 | 0.65 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.64 |
| ▸ | HTR3B | O95264 | 2/20 | 0.64 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.64 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.64 |
| ▸ | HTR7 | P34969 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 3/20 | 0.57 |
| ▸ | HTR6 | P50406 | 3/20 | 0.57 |
| ▸ | HTR2B | P41595 | 2/20 | 0.57 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL27617608 | 1.00 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL379449 | 0.98 | ADRB1 (1.00) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL7838014 | 0.98 | ADRB1 (1.00) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| Piperazine SCHEMBL28092166 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL1706127 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL7757785 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL5669070 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| Hydrochloric Acid SCHEMBL1024982 | 0.97 | ADRB1 (0.97) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL4526848 | 0.92 | ADRB1 (0.88) | ADRB1HTR2CHTR1AHTR1DHTR1B | |
| SCHEMBL11074672 | 0.85 | ADRB1 (0.76) | ADRB1NPC1MAPTDRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323478-B2 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION (US) | 2008-01-29 | — | — | US | disclosed |
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | BAKTHAVATCHALAM RAJAGOPAL (US) | 2004-11-18 | — | — | US | disclosed |
| US-6753336-B2 | EATING DISORDERS; SEXUAL DISORDERS | NEUROGEN CORPORATION | 2004-06-22 | — | — | US | disclosed |
| EP-1366030-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS | Neurogen Corporation (US) | 2003-12-03 | — | — | EP | disclosed |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2003-10-09 | — | — | US | disclosed |
| US-6569861-B2 | Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. | NEUROGEN CORPORATION | 2003-05-27 | — | — | US | disclosed |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | NEUROGEN CORPORATION | 2002-05-02 | — | — | US | disclosed |
| WO-2002004433-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229883-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | ADRB1 148/4885HTR1A 43/4885HTR1D 57/4885 |
| US-20020052383-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | ADRB1 139/4885HTR1A 42/4885HTR1D 51/4885 |
| US-20030191136-A1 | Melanin concentrating hormone receptor ligands | MCHR1, NPY1R, MCHR2 | ADRB1 148/4885HTR1A 43/4885HTR1D 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.